Indegene has announced a strategic collaboration with Microsoft to empower global life sciences companies to scale up the adoption of purpose-built, enterprise-grade GenAI services, thereby driving faster innovation at scale.
Indegene and Microsoft have committed to developing resources in highly specialised and skilled medical and technology tools to co-innovate generative AI services and workflows across commercial, medical, regulatory, and clinical functions.
Indegene counts 20 of the world’s top 20 biopharma companies among its clients.
”GenAI presents a once-in-a-decade opportunity for life sciences companies to modernize business processes and reimagine the effectiveness and efficiency of their operations throughout the value chain. Using GenAI, we’re closely working with many of our clients to solve specific business problems, with nearly 50 real-world use cases already in an advanced pilot stage”, Tarun Mathur, CTO, Indegene, said.
Some of the key use cases the strategic collaboration focuses on in the first phase, include:
- Content Super App: Using Azure OpenAI Service, the modular content value chain simplifies content creation and tagging for life sciences companies. This integrated approach offers a holistic view of the content value chain, enabling greater velocity, personalized content, and adoption of new conversation form factors. It also streamlines creative and video transformation while effectively engaging healthcare professionals (HCPs), patients and payers.
- Future-ready medical content value chain: Generative AI capabilities are revolutionizing the medical content value chain. From sourcing content from relevant literature articles to authoring core documents such as Clinical Study Reports (CSRs) and Protocols, Indegene’s solutions accelerate authoring processes and help ensure compliance across clinical and regulatory domains.
- Data Management and Analytics for Clinical Trials: Using Microsoft Fabric, Indegene’s solutions enhance the process of data ingestion and refinement, facilitate effortless reporting, and guarantee governance. This leads to proficient analytics, adherence to compliance, and nimbleness in business operations. It revolutionizes the way sales users work and provides a competitive advantage in the marketplace.
“According to a Microsoft-commissioned study conducted by IDC, a staggering 79% of healthcare organisations have now embraced AI. This demonstrates that the tangible business value of this transformation is indisputable. By seamlessly integrating Indegene’s domain knowledge with Microsoft Azure OpenAI Service and Microsoft Copilot, we stand at the forefront of advancing generative AI within the life sciences sector,” Alok Lall, chief operating officer, Microsoft India & South Asia, said.
